Summit Therapeutics Selected for Emerging Science Presentation at the 2018 American Academy of Neurology Annual Meeting
28 mars 2018 07h00 HE
|
Summit Therapeutics plc
OXFORD, United Kingdom and CAMBRIDGE, Mass., March 28, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM) announces that it has been selected for an Emerging Science dual oral...
Capricor Therapeutics to Present at Upcoming Oppenheimer and Needham Healthcare Conferences
21 mars 2018 07h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, March 21, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced that it will participate in two upcoming investment banking conferences, Oppenheimer’s 28th Annual...
Capricor Presents Fourth Quarter and Full Year 2017 Financial Results and Corporate Update
14 mars 2018 16h00 HE
|
Capricor Therapeutics, Inc.
Planning to Initiate HOPE-2 Clinical Trial To Host Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, March 14, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics...
Capricor Therapeutics to Present Fourth Quarter and Full Year 2017 Financial Results and Corporate Update on Wednesday, March 14
08 mars 2018 16h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, March 08, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for...
Summit Expands Enrolment in PhaseOut DMD Phase 2 Clinical Trial to Include Planned Additional Group
07 mars 2018 07h00 HE
|
Summit Therapeutics plc
Additional Group is Open to Patients Who Participated in Phase 1 Clinical Trials of EzutromidAllows Summit to Gather Additional Safety and Efficacy Data from a Broader Patient Population OXFORD,...
Capricor to Host Key Opinion Leader Lunch on March 9
28 févr. 2018 08h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced it will host a Key Opinion Leader Lunch in New York City on March 9 featuring four distinguished...
New Published Study Reports Cardiosphere-Derived Cells Improved Skeletal and Cardiac Muscle Function in Mouse Model of Duchenne Muscular Dystrophy
22 févr. 2018 13h23 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Feb. 22, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced the online publication in Stem Cell Reports of a new study by researchers at the Smidt Heart...
Capricor to Give Update on HOPE-2 Clinical Trial for CAP-1002 at International Conference on Duchenne Muscular Dystrophy
12 févr. 2018 08h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) will provide an update on HOPE-2, its trial for CAP-1002, the company’s lead investigational therapy for the...
Capricor Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Duchenne Muscular Dystrophy Therapy
05 févr. 2018 11h11 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced that the U.S. Food and Drug Administration (FDA) has granted CAP-1002, its lead investigational...
Ezutromid Significantly Reduced Muscle Damage in DMD Patients in 24-Week Interim Data From Summit’s PhaseOut DMD Clinical Trial
25 janv. 2018 07h00 HE
|
Summit Therapeutics plc
Increase in Utrophin Protein Expression ObservedSummit Accelerating Preparations for Pivotal Clinical TrialEzutromid is a Potential Disease-Modifying Treatment for the Entire DMD Patient...